We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+0.53%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$713M
AUM Growth
-$57.6M
Cap. Flow
-$67.5M
Cap. Flow %
-9.48%
Top 10 Hldgs %
81.58%
Holding
21
New
6
Increased
3
Reduced
8
Closed
4

Top Buys

1
ISRG icon
Intuitive Surgical
ISRG
+$77.5M
2
TMO icon
Thermo Fisher Scientific
TMO
+$71.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$60.3M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.7M
5
DXCM icon
DexCom
DXCM
+$19.3M

Top Sells

1
DHR icon
Danaher
DHR
+$79.4M
2
BSX icon
Boston Scientific
BSX
+$49.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$44.1M
4
JNJ icon
Johnson & Johnson
JNJ
+$43.9M
5
VERA icon
Vera Therapeutics
VERA
+$40.8M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$609B
$101M 14.22%
414,503
-188,640
-31% -$43.9M
ISRG icon
2
Intuitive Surgical
ISRG
$122B
$70.6M 9.91%
+153,250
New +$77.5M
TMO icon
3
Thermo Fisher Scientific
TMO
$198B
$65.1M 9.13%
+132,413
New +$71.9M
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$58.4M 8.2%
255,332
-9,683
-4% -$2.17M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$123B
$57.7M 8.1%
+129,314
New +$60.3M
LLY icon
6
Eli Lilly
LLY
$1.05T
$56.8M 7.98%
61,795
-1,489
-2% -$1.51M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.8B
$54.1M 7.59%
103,288
+17,265
+20% +$8.25M
DXCM icon
8
DexCom
DXCM
$29.6B
$43.8M 6.15%
698,158
+276,558
+66% +$19.3M
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$41.7M 5.86%
70,370
-50,551
-42% -$25.2M
NUVL icon
10
Nuvalent
NUVL
$31.6M 4.44%
308,506
+1,135
+0.4% +$116K
TEVA icon
11
Teva Pharmaceuticals
TEVA
$37.3B
$30.8M 4.32%
1,021,008
-414,857
-29% -$13.3M
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.5B
$30M 4.21%
+158,663
New +$27.7M
ARGX icon
13
argenx
ARGX
$53.8B
$23.1M 3.24%
31,635
-6,018
-16% -$4.71M
TARS icon
14
Tarsus Pharmaceuticals
TARS
$2.61B
$17.7M 2.49%
+252,588
New +$17.6M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.77B
$12.2M 1.71%
145,543
-476,860
-77% -$27.6M
AXSM icon
16
Axsome Therapeutics
AXSM
$11.8B
$10.5M 1.47%
62,116
-139,511
-69% -$24.1M
DFTX
17
Definium Therapeutics
DFTX
$5.88B
$6.99M 0.98%
+369,588
New +$6.27M
BSX icon
18
Boston Scientific
BSX
$65.4B
– –
-520,508
Closed -$49.6M
DHR icon
19
Danaher
DHR
$144B
– –
-346,875
Closed -$79.4M
IONS icon
20
Ionis Pharmaceuticals
IONS
$8.99B
– –
-557,174
Closed -$44.1M
VERA icon
21
Vera Therapeutics
VERA
$2.76B
– –
-805,689
Closed -$40.8M

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Tri Locum Partners held 21 positions worth $713M, down 7.5% from $770M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Tri Locum Partners withdrew a net $67.5M in Q1 2026, closing 4 positions and reducing 8 holdings. Its most notable exit was Danaher, an estimated $79.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Tri Locum Partners opened a new position in Intuitive Surgical worth $70.6M.

  • Tri Locum Partners's largest Q1 2026 buy was Intuitive Surgical: 153,250 shares worth $70.6M.
  • Tri Locum Partners added most to DexCom in Q1 2026, an estimated $19.3M increase.
  • Tri Locum Partners's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $43.9M.
  • Tri Locum Partners fully exited Danaher in Q1 2026, selling an estimated $79.4M.
  • Tri Locum Partners's ten largest holdings make up 82% of its $713M portfolio in Q1 2026.
  • Tri Locum Partners opened 6 new positions and closed 4 in Q1 2026.
  • Tri Locum Partners's portfolio value fell 7.5% quarter-over-quarter to $713M.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.